Amgen Inc. (Nasdaq: AMGN), a global biotechnology company, posted third-quarter 2023 earnings per share (EPS) of $4.96, surpassing the consensus EPS estimate of $4.66. The company's quarterly revenues stood at $6.90 billion, slightly below analysts' projections of $6.94 billion.

For the full year 2023, Amgen offered an outlook with total revenues expected to fall within the range of $28.0 billion to $28.4 billion, and adjusted EPS anticipated in the range of $18.20 to $18.80. The consensus estimate points to an EPS of $18.36 on revenue of $27.6 billion for the period.

$AMGN was trading at $261.83 in pre-market, down $1.36 (-0.52%).

In separate news, Repligen Corporation (Nasdaq: RGEN), a bioprocessing company, reported a strong performance in the third quarter of 2023, with earnings of $0.23 per share, beating analyst estimates of $0.17. The company's quarterly revenues amounted to $141.19 million, slightly above analysts' expected $140.64 million in revenue.

Repligen adjusted its full-year fiscal 2023 earnings per share outlook, revising it down to the range of $1.70 to $1.76 from the previous guidance range of $1.72 to $1.80, contrasting with the consensus EPS estimate of $1.74 for the period.

$RGEN was trading at $120.00, up by $5.83 (+5.11%) in pre-market.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)